The Carlyle Group Inc. (CG) Revenue by Segment

Executive TeamFinancialsSegments
Shareholders

Carlyle revenue by segment at a glance

In Q3 fiscal 2023 (the quarter ended September 30, 2023), Carlyle's largest business segment was Global, with $776.60 million or 91% of revenue, down 44.6% from a year earlier. Next: Global Investment Solutions (9%).

By product or service, Principal Investment Income (Loss) brought in 61% and Performance Allocations brought in 39% of revenue in Q2 fiscal 2026.

The fastest-growing business segment from a year earlier was Global Investment Solutions (-41.9%).

From company filings, in USD; latest quarter ended September 30, 2023; quarterly data from Q3 fiscal 2017.

CG logo

The Carlyle Group Inc.

CGUnited States
Financial Services

Revenue breakdown

Fiscal quarters, from company filings

Carlyle revenue by business segment, last 4 quarters

Business segmentQ2 FY26Q1 FY26Q2 FY25Q1 FY25Share
Global$1.1B$750.9M$984.0M$1.0B91%
Global Investment Solutions––––9%

In USD, fiscal quarters as reported; share = part of Q3 FY23 revenue.

Carlyle revenue by product or service, last 4 quarters

Product or serviceQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
Principal Investment Income (Loss)$69.2M$64.4M$87.7M$55.2M61%
Performance Allocations$44.7M––$638.8M39%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are Carlyle's business segments?

Global and Global Investment Solutions (as reported for Q3 fiscal 2023).

Which business segment makes the most money for Carlyle?

Global: $776.60 million, or 91% of revenue, in Q3 fiscal 2023.

What are Carlyle's main products and services?

By revenue in Q2 fiscal 2026: Principal Investment Income (Loss) (61%) and Performance Allocations (39%).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube